Table 4 Subgroup analysis of treatment effect of scaffold embedded chABC on motor function recovery after SCI compared to non-treated animals
From: Sustained delivery of chABC improves functional recovery after a spine injury
Subgroup | Number of experiments | Heterogeneity (p value) | SMD (95% CI) | p value | ||
|---|---|---|---|---|---|---|
SCI model | ||||||
 Contusion-compression | 4 | 87.3% (< 0.0001) | 1.4 | − 0.52 | 3.31 | 0.15 |
 Transection–hemisection | 5 | 87% (< 0.0001) | 2.458 | 0.688 | 4.228 | 0.006 |
Severity of SCI | ||||||
 Severe | 5 | 87.8% (< 0.0001) | 2.694 | 0.793 | 4.595 | 0.005 |
 Moderate | 4 | 85.7% (0.001) | 1.146 | − 0.567 | 2.858 | 0.19 |
Transplantation type | ||||||
 Injection | 5 | 85.7% (< 0.0001) | 1.45 | − 0.093 | 2.997 | 0.065 |
 Implant | 4 | 90.0% (< 0.0001) | 2.801 | 0.399 | 5.204 | 0.022 |
Follow-up time | ||||||
 < 8 weeks | 6 | 67.2% (0.0091) | 1.55 | 0.572 | 2.527 | 0.002 |
 ≥ 8 weeks | 3 | 95.5% (< 0.0000) | 3.11 | − 0.89 | 7.1 | 0.128 |
 Overall | 9 | 86.8% (< 0.0001) | 1.95 | 0.708 | 3.198 | 0.002 |